Premium
P2‐291: SLEEP DISTURBANCE AND RISK OF DEMENTIA AMONG OLDER VETERANS
Author(s) -
Yaffe Kristine,
Nettiksimmons Jasmine,
Byers Amy L.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.969
Subject(s) - medicine , dementia , sleep disorder , sleep apnea , hazard ratio , cohort , depression (economics) , obstructive sleep apnea , insomnia , cohort study , proportional hazards model , psychiatry , pediatrics , physical therapy , disease , confidence interval , economics , macroeconomics
where advanced biomarkers are incorporated. Therefore, the prospective and longitudinal Swedish BioFINDER study has been initiated to focus on: (1) key disease mechanisms of AD and other neurodegenerative diseases, (2) identifying diagnostic biomarkers, (3) mapping the temporal disease pattern, and (4) examining the disease heterogeneity of dementia disorders to assist in the development of a new pathology-based disease classification. BioFINDER consists of three cohorts: (A) 500 patients with MCS, (B) 350 healthy elderly, and (C) 300 patients with parkinsonian disorders. The aim of this presentation is to show the methodology, baseline characteristics and preliminary results from cohort A. Methods: Ongoing from 2010-2014, 500 consecutive non-demented patients with subjective or objective cognitive impairment are included. At baseline they undergo neuropsychological, neurological and psychiatric assessments, lumbar puncture (LP), blood analysis, physical therapy, and magnetic resonance imaging (MRI) including resting state functional MRI, diffusion tension and kurtosis imaging, and MR spectroscopy. Annual follow-up with cognitive assessments take place over four years. After two years, MRI, LP and neuropsychological evaluations are repeated. Approximately half of the patients undergo amyloid PET using [18 F]flutemetamol at baseline and follow-up. Results: The different types of cognitive impairment (including subjective, amnestic and non-amnestic mild cognitive impairment) will be presented with reference to amyloid PET, CSF biomarkers, and hippocampus atrophy data. The study design will be compared with other large existing cohorts such as the ADNI, AiBL and Mayo Clinic Study of Aging. The first cross-sectional results will also be presented. Conclusions: The Swedish BioFINDER study has included a clinically relevant cohort of non-demented, consecutive patients with cognitive impairment of subjective, amnestic and non-amnestic variants, who have been investigated with advanced biomarkers. The design makes it a suitable complementary study to previous large population-based cohorts and research studies with selected, non-consecutive subjects.